Germany 1986.

Methods	Randomized trial of 1 3‐month and 2 6‐month regimens
Participants	363 patients with sputum positive TB entered Excluded from relapse analysis: Prerandomization ineligibility: 23/363 (6%) Side effects: 21/363 (6%) Protocol violations, lack of cooperation, other: 19/363 (5%)
Interventions	3SHRZ 6SHRZI 3SHRZ/3SHZI Dosages: not given
Outcomes	Bacteriologic relapse at 36‐48 months after starting treatment.
Notes	3‐month regimen stopped enrollment early because of poor results, leading to imbalance among treatment groups. 17% of enrolled patients excluded from analysis.